Covance Acquires Medaxial
News May 23, 2014
Covance has announced that it has acquired Medaxial, a London-based value communication consultancy. The company specializes in offering clients an integrated approach to market access strategy, health economic modeling, and data dissemination services, and focuses on defining and communicating the value of a biopharmaceutical product or medical device to healthcare payers and the stakeholders who influence them.
"Covance is a leader in the rapidly growing sector of market access and reimbursement. Medaxial, with their proven expertise in optimizing data-driven, solution-focused communication of a medical product's value will further complement our market access offerings," said Marc Ginsky, Vice President and General Manager, Covance Market Access. "Proactive and effective communication of clinical and economic value is critical to help clients navigate an increasingly complex drug development and payment landscape, as they strive to provide innovative medical products to patients."
With the acquisition of Medaxial, Covance's market access services, which currently has offices in Gaithersburg, Md., Greenfield, Ind., San Diego and Sydney, will be better positioned to serve clients worldwide. In addition to Medaxial's corporate headquarters in London, the company has employees in New York and Antwerp, Belgium.
"Our capabilities and our commitment to client service are in line with Covance's commitment to operational and service excellence," said Paul Mcloughlin, co-founder and Director, Technology and Design, Medaxial. "This acquisition will provide clients with the benefits of a global consultancy group with local expertise." Mcloughlin, along with John Fanshawe, co-founder and Managing Director at Medaxial, will continue working with the company after the acquisition is completed.
"This acquisition will enhance Covance's ability to bring value communication solutions to our clients, beginning early in drug development and continuing through regulatory approval, reimbursement, and commercial success," said Ginsky.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018